Compass (COMP) stock fell 2.4% in Friday midday trading following a report that Senator Elizabeth Warren (D-MA) questioned ...

Lawmakers urge DOJ to detail its review of the $1.6B Compass-Anywhere merger, citing risks to competition and housing costs.

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

The multinational coffee company will continue to operate 17 D.C.-area cafes under the Compass brand.

Compass Point is pleased to announce the expansion of its Real Estate Research Team with the addition of Mr. Robert ...